Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers in Meningioma

Version 1 : Received: 22 July 2021 / Approved: 23 July 2021 / Online: 23 July 2021 (22:06:24 CEST)

A peer-reviewed article of this Preprint also exists.

Roesler, R.; Souza, B.K.; Isolan, G.R. Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma. Int. J. Mol. Sci. 2021, 22, 11352. Roesler, R.; Souza, B.K.; Isolan, G.R. Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma. Int. J. Mol. Sci. 2021, 22, 11352.

Abstract

Meningioma (MGM) is the most common type of intracranial tumor in adults. The validation of novel prognostic biomarkers to better inform tumor stratification and clinical prognosis is urgently needed. Many molecular and cellular alterations have been described in MGM tumors over the past few years, providing a rational basis for the identification of biomarkers and therapeutic targets. The role of receptor tyrosine kinase (RTKs), including those of the ErbB family of receptors, as oncogenes has been well established in several cancer types. Here, we review histological, molecular, and clinical evidence suggesting that RTKs, including the epidermal growth factor receptor (EGFR, ErbB 1), as well as other members of the ErbB family, may be useful as biomarkers in MGM.

Keywords

epidermal growth factor receptor; ErbB; biomarker; meningioma; intracranial tumor

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.